CVRx (NASDAQ:CVRX) Issues Earnings Results, Beats Estimates By $0.01 EPS

Posted by Brian Himes on May 11th, 2026

CVRx (NASDAQ:CVRX – Get Free Report) released its earnings results on Monday. The company reported ($0.50) EPS for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.01, Zacks reports. CVRx had a negative return on equity of 99.32% and a negative net margin of 94.10%.

Here are the key takeaways from CVRx’s conference call:

CVRx reported a strong Q1, with total revenue of $14.8 million (+20%), U.S. revenue of $13.7 million (+22%), an improved gross margin of 87%, and a slightly smaller net loss, signaling that prior investments are beginning to drive commercial results.
The transition to Category I CPT codes is a major reimbursement win, but new Medicare Advantage rules and payer automation produced a March dip in 30‑day prior‑authorization approvals (Q1 rate 46%), creating a near‑term administrative headwind that may add variability to access and timing of revenue.
The BENEFIT‑HF randomized trial is underway (first site activated, first patient enrolled) and, if successful, could expand the addressable market from ~339,000 to >980,000 patients (~$30 billion TAM), although regulatory and enrollment timelines extend over several years.
Commercial execution is improving — U.S. territories increased to 56 and active implanting centers to 257, and management reports higher utilization at targeted centers driven by a program‑focused sales approach, supporting sustained U.S. growth.
Management reaffirmed 2026 guidance (revenue $63–67M, gross margin 85–87%, operating expenses $103–107M) despite the Q1 beat, reflecting a cautious posture early in the year while monitoring reimbursement and trial rollout trends.

CVRx Trading Up 1.3%

NASDAQ CVRX traded up $0.09 during trading on Monday, hitting $6.92. 361,360 shares of the company’s stock traded hands, compared to its average volume of 327,421. The stock has a fifty day moving average of $8.05 and a two-hundred day moving average of $8.05. The company has a debt-to-equity ratio of 1.26, a current ratio of 7.63 and a quick ratio of 6.72. CVRx has a 12-month low of $4.30 and a 12-month high of $11.30. The firm has a market cap of $182.90 million, a P/E ratio of -3.38 and a beta of 0.90.

Insider Transactions at CVRx

In other CVRx news, Director Mudit K. Jain purchased 46,800 shares of the business’s stock in a transaction on Friday, February 20th. The stock was acquired at an average cost of $6.36 per share, for a total transaction of $297,648.00. Following the completion of the transaction, the director directly owned 980,183 shares in the company, valued at approximately $6,233,963.88. This represents a 5.01% increase in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 18.90% of the stock is currently owned by insiders.

Institutional Trading of CVRx

Several institutional investors have recently added to or reduced their stakes in the business. Alliancebernstein L.P. boosted its position in CVRx by 10.7% during the third quarter. Alliancebernstein L.P. now owns 17,560 shares of the company’s stock valued at $142,000 after buying an additional 1,700 shares during the period. Cresset Asset Management LLC boosted its position in CVRx by 3.5% during the second quarter. Cresset Asset Management LLC now owns 53,542 shares of the company’s stock valued at $315,000 after buying an additional 1,823 shares during the period. Barclays PLC boosted its position in CVRx by 9.8% during the fourth quarter. Barclays PLC now owns 25,262 shares of the company’s stock valued at $179,000 after buying an additional 2,257 shares during the period. BNP Paribas Financial Markets boosted its position in CVRx by 7.1% during the third quarter. BNP Paribas Financial Markets now owns 57,447 shares of the company’s stock valued at $464,000 after buying an additional 3,804 shares during the period. Finally, Bridgeway Capital Management LLC boosted its position in CVRx by 8.9% during the third quarter. Bridgeway Capital Management LLC now owns 54,000 shares of the company’s stock valued at $436,000 after buying an additional 4,400 shares during the period. 75.27% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms recently commented on CVRX. Cantor Fitzgerald raised CVRx to a “strong-buy” rating in a research note on Tuesday, February 17th. Canaccord Genuity Group reissued a “buy” rating and issued a $10.00 target price on shares of CVRx in a research note on Tuesday, April 14th. Finally, Weiss Ratings cut CVRx from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $11.50.

Read Our Latest Stock Report on CVRx

About CVRx

(Get Free Report)

CVRx, Inc is a clinical-stage medical device company focused on developing a neuromodulation platform therapy for patients with cardiovascular disease. The company’s flagship product, the Barostim™ system, delivers targeted electrical stimulation to the carotid baroreceptors with the goal of modulating the body’s natural blood pressure control mechanisms. This minimally invasive, implantable therapy is designed to address unmet needs in individuals suffering from hypertension and heart failure.

The Barostim system is currently being evaluated in multiple clinical trials, including studies in resistant hypertension and advanced heart failure.

Earnings History for CVRx (NASDAQ:CVRX)

Receive News & Ratings for CVRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVRx and related companies with MarketBeat.com's FREE daily email newsletter.